Physician profile
Amy Hansen
NPI 1295975076
$1,469.32
in general payments reported to CMS, 2019-2025
24 companies · $71.18 in 2025
The $71.18 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $372 · 2022: $309 · 2023: $396 · 2024: $321 · 2025: $71.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $379.15 | 2021-2024 | |
| Lilly USA, LLC | $115.62 | 2021-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $90.50 | 2021-2023 | Gardasil 9, Vaxelis, M-M-R II |
| Astrazeneca Pharmaceuticals LP | $87.96 | 2022-2024 | Breztri, Airsupra |
| Exact Sciences Corporation | $87.47 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $87.04 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $81.95 | 2021-2024 | Prolia, Evenity |
| Corium, LLC | $81.75 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $67.84 | 2023-2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $63.90 | 2021-2023 | |
| Viiv Healthcare Company | $37.52 | 2024 | Apretude |
| Glaxosmithkline, LLC. | $37.02 | 2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.79 | 2024 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $27.83 | 2023 | Sunosi |
| Seqirus USA INC | $26.37 | 2025 | Flucelvax |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $24.84 | 2022 | |
| Exeltis, USA INC. | $22.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.31 | 2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.52 | 2023 | |
| Evofem Biosciences, INC. | $18.47 | 2021 | |
| Cranial Technologies, INC | $16.00 | 2023 | Doc Band |
| Lucid Diagnostics INC. | $15.18 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.60 | 2022 | |
| Sanofi Pasteur INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.